ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-OR029

Ubiquitin Carboxyl-Terminal Hydrolase L1 Is a Podocyte Target of IgG Antibodies in Idiopathic Nephrotic Syndrome (INS)

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Deschênes, Georges, Hospital Robert Debre, Paris, France
  • Jamin, Agnes, INSERM U1149 & ELR8252 CNRS, 75018 Paris, France
  • Berthelot, Laureline, INSERM U699, Paris, France
  • Monteiro, Renato C., Bichat Medical School, Paris, France
Background

The efficiency of B cell-depleting treatments highlights the involvement of B cells in INS. This study searched for identifying antibodies (Abs) directed against podocytes in patients with INS.

Methods

The study was performed using a biobank including 86 patients sampled at various stages of INS and 76 controls. Fractions of plasma obtained by size exclusion chromatography and tested on cultured podocyte adhesion; specificities of IgG Abs contained in the plasma fraction of interest were studied through immunoprecipitation of a podocyte lysate then identification of cognate antigens by liquid chromatography-mass spectrometry.

Results

Cultured podocyte detachment was observed with one specific plasma fraction in 16/34 INS relapsing patients, 1/11 INS patients in remission and 0/25 controls. IgG were isolated from this specific plasma fraction in 3 INS relapsing patients (all detaching cultured podocytes), 3 from the same INS patients in remission (all not detaching cultured podocytes) and in 3 controls, then used to immunoprecipitate a podocyte lysate. Comparative proteomic analysis allowed selecting 5 proteins according to statistical and biological criteria. Specific Abs were tested and only anti-Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) IgG led to podocyte detachment. Pre-incubation of either anti-UCHL1 IgG Abs or plasma fractions with recombinant UCHL1 prevented podocyte detachment. Plasma levels of anti-UCHL1 IgG Abs were increased in 18/42 relapsing INS patients over the highest level of 38 controls (median=0.20 AU/*g of total IgG;IQ0.15-0.29;range0.07-0.85). For those 18 patients, the level of anti-UCHL1 IgG Abs in 43 samples available at various stage of INS was confirmed to be significantly higher in relapse (n=23;median=1.22AU/µg of total IgG; IQ 0.92-1.90) compared to remission (n=20;median=0.51;IQ 0.33-0.77;p<0.001). In those 18 INS patients, proteinuria correlated with anti-UCHL1 IgG Abs level (n=43,r=0.57,p<0.001).

Conclusion

UCHL1 is involved in the adhesion of cultured podocytes. UCHL1 is a target of circulating IgG Abs in a subset of relapsing INS patients.

Funding

  • Private Foundation Support